252
Views
0
CrossRef citations to date
0
Altmetric
Articles

Short-term ciprofloxacin prophylaxis for prostate biopsy and risk of aortic aneurysm. Nationwide, population-based cohort study

, ORCID Icon, , &
Pages 221-226 | Received 07 Dec 2020, Accepted 07 Apr 2021, Published online: 28 Apr 2021

References

  • Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:678.
  • Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open. 2015;5(11):1–9.
  • Lee C-C, Lee M-tG, Chen Y-S, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Internal Med. 2015;175(11):1839–1847.
  • Corps AN, Harrall RL, Curry VA, et al. Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1β in human tendon-derived cells. Arthritis Rheumatol. 2002;46(11):3034–3040.
  • Chang H-N, Pang J-HS, Chen CPC, et al. The effect of aging on migration, proliferation, and collagen expression of tenocytes in response to ciprofloxacin. J Orthop Res. 2012;30(5):764–768.
  • Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Quinolone and fluoroquinolone Article-31 referral. European Medicines Agency; 2019.
  • European Association of Urololgy Guidelines. Urological infections 2020. [cited 2020 0204].
  • Yang L, Gao L, Chen Y, et al. Prophylactic antibiotics in prostate biopsy: a meta-analysis based on randomized controlled trials. Surg Infect. 2015;16(6):733–747.
  • Styrke J, Resare S, Lundström K, et al. Current routines for antibiotic prophylaxis prior to transrectal prostate biopsy: a national survey to all urology clinics in Sweden. F1000research. 2020;9:58.
  • Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort Profile: the National Prostate Cancer register of sweden and prostate cancer data base sweden 2.0. Int J Epidemiol. 2013;42(4):956–967.
  • Barlow L,   KW, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33. eng.
  • Brooke HL, Talbäck M, Hörnblad J, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765–773.
  • Wallerstedt SM, Wettermark B, Hoffmann M. The first decade with the Swedish prescribed drug register – a systematic review of the output in the scientific literature. Basic Clin Pharmacol Toxicol. 2016;119(5):464–469.
  • Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
  • Statistics Sweden. Longitudinal integrated database for health insurance and labour market studies (LISA) 2019. [cited 2019 2019-12-13]. Available from: https://www.scb.se/en/services/guidance-for-researchers-and-universities/vilka-mikrodata-finns/longitudinella-register/longitudinal-integrated-database-for-health-insurance-and-labour-market-studies-lisa/
  • Ekbom A. The Swedish multi-generation register. Methods Mol Biol. 2011;675:615–620.
  • Hagel E, Garmo H, Bill-Axelson A, et al. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol. 2009;43(5):342–349.
  • Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
  • James LM, Andrew JA, Robert RB, et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 2016;14(1):19–30.
  • Nationellt Vårdprogram Prostatcancer. In: Centre RC, editor. 2020.
  • Landenhed M, Engström G, Gottsäter A, et al. Risk profiles for aortic dissection and ruptured or surgically treated aneurysms: a prospective cohort study. J Am Heart Assoc. 2015;4(1):e001513.
  • Carlsson S, Bratt O, Stattin P, et al. Current routines for transrectal ultrasound-guided prostate biopsy: a web-based survey by the Swedish Urology Network. Scand J Urol Nephrol. 2012;46(6):405–410.
  • Bonkat G, Pilatz A, Wagenlehner F. Time to adapt our practice? the european commission has restricted the use of fluoroquinolones since march 2019. Eur Urol. 2019;76(3):273–275.
  • Bonkat G, Wagenlehner F. In the line of fire: should urologists stop prescribing fluoroquinolones as default? Eur Urol. 2019;75(2):205–207.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.